Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Pediatric Dermatology Treatment Market size is expected to register around 9.3% CAGR during the forecast period i.e., between 2025-2037.
The growth of the market can be attributed to the increasing prevalence of skin disorders around the world, and rise in awareness levels associated with the progression of dermatology diseases. As per the World Psoriasis Day consortium, as of 2020, 125 million people around the world were suffering from psoriasis, which is about 2 to 3 percent of the total population. Along with these, growing incidences of weakened immune systems among children as a result of sedentary lifestyle is also expected to drive significant growth to the market in the forthcoming years. Furthermore, high healthcare expenditures in developed countries, and surge in technological advancements to develop improved treatment options for skin diseases are projected to offer lucrative opportunities for pediatric dermatology treatment market growth in the near future.
Pediatric Dermatology Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Skin Disorders Worldwide
- Rising Awareness Levels Associated with the Progression of Dermatology Diseases
Challenges
- Side Effects of Certain Classes of Treatment Drugs
Pediatric Dermatology Treatment Market: Key Insights
|
2023 |
|
|
Forecast Year |
2024–2036 |
|
CAGR |
9.3% |
|
Regional Scope |
|
Pediatric Dermatology Treatment Segmentation
The market is segmented by application into alopecia, erythromelalgia, psoriasis, atopic dermatitis, and others, out of which, the psoriasis segment is anticipated to hold the largest share in the global pediatric dermatology treatment market. This can be accounted to the increasing occurrence of psoriasis among children across the globe, and growing development of new medications for treating this condition. Additionally, on the basis of end user, the hospitals segment is assessed to acquire the largest share during the forecast period, which can be credited to the high preference of patients to be treated by a healthcare professional in a hospital facility. Apart from this, high number of admissions in hospitals is also predicted to fuel the market segment growth in the future.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Application |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPediatric Dermatology Treatment Industry - Regional Synopsis
On the basis of geographical analysis, the global pediatric dermatology treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific industry is anticipated to hold largest revenue share by 2037, impelled by large patient pool and growing number of incidences of dermatology diseases among children in the region. Moreover, the market in North America is expected to occupy the largest share during the forecast period ascribing to the high healthcare spending, and increasing awareness about skin diseases in the region. As per the Centers for Medicare & Medicaid Services, the healthcare spending in the United States grew 4.6 percent in 2019, reaching a value of USD 3.8 trillion. As a share of the nation's Gross Domestic Product, health spending accounted for 17.7 percent that year. In addition, strong presence of pharmaceutical companies is also anticipated to bolster the pediatric dermatology treatment market growth in the region in the coming years.
Companies Dominating the Pediatric Dermatology Treatment Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen Inc.
- AbbVie Inc.
- Almirall SA
- Bausch Health Companies Inc.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Sanofi S.A.
- Bristol Myers Squibb Company
In the News
-
February 2021- Bristol Myers Squibb announced positive results from POETYK PSO-2, the second Phase III clinical trial evaluating deucravacitinib, which is a novel, selective tyrosine kinase 2 inhibitor for treating patients with moderate to severe plaque psoriasis.
-
May 2020- Sanofi S.A. received the United States Food and Drug Administration for Dupixent for the treatment of moderate-to-severe atopic dermatitis.
Author Credits: Radhika Pawar
- Report ID: 3742
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
